20 June 2013
Keywords: biogen, serono, head, ms, market, expect, major
Article | 10 June 2002
Biogen should expect major competition from Serono in the multiplesclerosis market, says a new study from Decision Resources. Biogen's
Avonex ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 June 2002
17 June 2002
19 June 2013
© 2013 thepharmaletter.com